Novo Nordisk locks horns with Pfizer in late bid for Metsera
While Pfizer called the bid “reckless”, Metsera disagrees, stating that it will review the “superior proposal”.
While Pfizer called the bid “reckless”, Metsera disagrees, stating that it will review the “superior proposal”.
